PET-CT Scanning Services Market

The global market for PET-CT scanning services is estimated to value at US$ 207.2 Bn by the end of 2031 from US$ 146.3 Bn in 2024. The market is projected to expand at a CAGR of 5.1% during the forecast period from 2024 to 2031.

PET-CT scanning services combine the capabilities of two advanced imaging techniques: positron emission tomography (PET) and computed tomography (CT). This hybrid imaging modality provides detailed information about the structure and function of organs and tissues within the body.

PET-CT scanners integrate PET and CT components into a single device. This allows for simultaneous acquisition of both functional (PET) and anatomical (CT) information during a single imaging session. By combining these modalities, PET-CT scans provide comprehensive information about both the structure and function of tissues and organs. Such scanning services have witnessed remarkable growth due to continuous advancements in imaging technology. These advancements have significantly improved the accuracy, speed, and versatility of PET-CT scanners, driving their adoption across various medical specialties.

PET-CT scanning services offer a powerful tool for the diagnosis, staging, and management of a wide range of medical conditions, providing detailed information about both the structure and function of tissues and organs within the body.

Technological innovations have led to the development of PET-CT scanners with high image resolution, allowing for better visualization of anatomical structures and metabolic activity within the body. Higher resolution images provide clinicians with more detailed information, enhancing diagnostic accuracy and enabling earlier detection of diseases.

Increasing Prevalence of Cancer Remains a Key Driver for Market

PET-CT scans are extensively used in oncology for diagnosing, staging, and monitoring various types of cancers. With the growing prevalence of cancer worldwide, the demand for PET-CT scanning services has been rising steadily. PET-CT scans offer high sensitivity and specificity in detecting cancerous lesions, often at an early stage when other imaging modalities may fail to detect them. This accuracy aids in early diagnosis, which is crucial for initiating timely treatment and improving patient outcomes.

PET-CT scans enable clinicians to assess the effectiveness of cancer treatment by visualizing changes in metabolic activity and tumor size over time. This ability to monitor treatment response helps in adjusting therapy regimens as needed, optimizing patient care, and avoiding unnecessary procedures.

PET-CT scans are important to clinical research and drug development programs aimed at discovering new cancer therapies and evaluating their efficacy in clinical trials. The demand for PET-CT imaging services market is consequently driven by the expanding pipeline of oncology drugs and the requirement for robust imaging endpoints in clinical studies.

The Expanding Scope of PET-CT Applications

PET-CT scans are being increasingly used in new indications beyond oncology, such as cardiology and neurology. The expanding scope of PET-CT applications is driving market growth as it opens up new revenue streams for service providers. While PET-CT scans have traditionally been associated with oncology for detecting and staging cancers, their applications have expanded to other medical fields.

PET-CT is now utilized in cardiology for assessing myocardial viability, detecting coronary artery disease, and evaluating cardiac sarcoidosis. In neurology, PET-CT aids in diagnosing Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. This diversification of applications increases the demand for PET-CT scanning services.

PET-CT imaging is increasingly used in infectious disease management, particularly in detecting and monitoring infections such as tuberculosis, HIV-related complications, and fungal infections. PET-CT helps in visualizing inflammatory processes and assessing the response to antimicrobial therapies, contributing to improved patient care and management of infectious diseases.  

The expanding scope of PET-CT applications beyond oncology to encompass various medical specialties, infectious diseases, inflammatory disorders, theranostics, and preventive medicine initiatives significantly contributes to the growth of the PET-CT scanning services market. As the utility of PET-CT imaging continues to evolve, driven by technological advancements and clinical research, the demand for PET-CT scanning services is expected to further expand in the future.

Rising Awareness and Early detection

Increased awareness about the benefits of early detection and diagnosis of diseases has led to a rise in the demand for PET-CT scans, especially among high-risk populations. Early detection allows for timely intervention and better treatment outcomes. Increased awareness campaigns and education initiatives empower individuals to take proactive steps towards their health. As people become more knowledgeable about the benefits of early detection and diagnosis of diseases, including cancer and other serious conditions, they are more likely to seek out screening options such as PET-CT scans.

PET-CT scans offer several advantages in early disease detection, including high sensitivity for detecting small lesions, ability to visualize metabolic changes indicative of disease, and comprehensive whole-body imaging capabilities. As patients and physicians recognize the superiority of PET-CT imaging in certain clinical scenarios, there is an increased demand for PET-CT scanners to meet diagnostic needs.

Early detection of diseases through PET-CT scanning can lead to more effective treatment interventions at earlier stages of disease progression. This can result in reduced healthcare costs associated with advanced-stage treatments, hospitalizations, and long-term care. As healthcare systems focus on cost-effective strategies, investing in PET-CT scanners for early detection becomes a priority.

Limited Access in Developing Regions

PET-CT scanners are predominantly available in urban centers and tertiary care hospitals, leading to disparities in access to imaging services, particularly in rural and underserved areas. Infrastructure limitations, including lack of trained personnel, inadequate healthcare facilities, and logistical challenges, hinder the widespread adoption of PET-CT scanning services in developing regions.

Developing regions often lack the necessary healthcare infrastructure to support PET-CT scanning services. This includes insufficient numbers of hospitals or medical centers equipped with PET-CT scanners, as well as inadequate facilities for radiotracer production, storage, and disposal. Without the requisite infrastructure, access to PET-CT imaging remains restricted in these regions.

Rural and remote areas in developing regions face geographical barriers that impede access to healthcare services, including PET-CT scanning. Limited transportation networks, long distances to healthcare facilities, and challenging terrain make it difficult for patients to access PET-CT scanners, resulting in disparities in healthcare access and outcomes.

Limited Availability of Radiotracers

Radiotracers are essential for PET imaging as they enable the visualization of specific biological processes and molecular targets within the body. The availability of radiotracers for PET imaging is essential for conducting PET-CT scans. However, the production and distribution of radiotracers may be constrained by logistical challenges, regulatory requirements, and supply chain disruptions. Limited availability of specific radiotracers may restrict the range of clinical applications and hinder market expansion.

Certain PET-CT imaging studies require specific radiotracers tailored to particular clinical indications. The scarcity of these radiotracers limits the types of scans that can be performed, reducing the versatility and utility of PET-CT imaging in diagnosing and managing diverse medical conditions, including cancer, cardiovascular diseases, and neurological disorders.

The limited availability of radiotracers hampers research and development efforts aimed at exploring new clinical applications and advancing PET imaging technology. Without access to a diverse range of radiotracers, researchers may face challenges in conducting studies, evaluating novel imaging techniques, and developing innovative diagnostic and therapeutic strategies.

Expansion into Emerging Market

The PET-CT scanning services market has significant growth potential in emerging markets, driven by increasing healthcare infrastructure development, rising disease burden, and growing awareness of the benefits of medical imaging services.

Emerging markets are experiencing a rising prevalence of cancer, cardiovascular diseases, and other chronic conditions, increasing the demand for diagnostic imaging services like PET-CT scans. As the burden of disease grows, there is a great need for early detection, accurate diagnosis, and personalized treatment, creating opportunities for PET-CT scanning services to address unmet clinical needs.

Emerging markets are investing in expanding healthcare infrastructure, including the installation of PET-CT scanners in hospitals and medical centers. The growing availability of PET-CT scanning services in these regions improves access to advanced diagnostic imaging for a larger patient population, driving market growth.

Personalized Medicine and Theranostics

PET-CT imaging plays a crucial role in identifying patients who are most likely to respond to specific targeted therapies. By visualizing biomarkers and molecular targets within the body, PET-CT scans help clinicians select appropriate treatments based on the patient's unique disease characteristics, optimizing therapeutic outcomes and minimizing adverse effects.

Theranostics involves the use of the same radiotracer for both diagnostic imaging and targeted radionuclide therapy. PET-CT scans provide valuable information about tumor biology, receptor expression, and treatment response, enabling clinicians to personalize treatment regimens and monitor therapeutic efficacy in real-time. Theranostic approaches hold great promise for precision medicine in oncology and other disease areas, offering more effective and personalized treatment options for patients.

Ongoing research and development efforts are focused on identifying novel radiotracers targeting specific molecular pathways and disease markers. These emerging radiotracers have the potential to expand the clinical applications of PET-CT imaging, opening up new opportunities for early diagnosis, targeted therapy, and personalized medicine across a wide range of medical specialties.

Stationary Scanners Led the PET-CT Scanner Services Market

Stationary scanners have witnessed significant technological advancements over the years, leading to enhanced imaging capabilities, improved resolution, and better accuracy in diagnosis. These advancements have made them more reliable and preferred by healthcare professionals. While the initial investment for stationary PET-CT scanners may be higher, they offer long-term cost-effectiveness due to lower maintenance costs and higher durability. Additionally, their ability to handle a larger number of patients translates to better revenue generation for healthcare facilities.

Stationary scanners are designed to handle higher patient volumes efficiently. Their fixed installation in hospitals and imaging centers allows for continuous operation, enabling healthcare providers to accommodate more patients within a given timeframe.

North America Poised for Notable Growth in the Market

North America, particularly the United States, boasts a highly developed healthcare infrastructure with well-established hospitals, imaging centers, and medical facilities. The region's robust healthcare system enables widespread access to advanced diagnostic imaging services, including PET-CT scans, for patients across the continent.

The region faces a substantial burden of chronic diseases, including cancer, cardiovascular diseases, and neurological disorders, which necessitates extensive utilization of diagnostic imaging services for early detection, staging, and treatment monitoring. PET-CT scanning plays a crucial role in the diagnosis and management of these diseases, contributing to its widespread adoption and market dominance in the region.

The competitive landscape for the PET-CT scanning services market is characterized by the presence of several global and regional players offering a range of imaging services, including PET-CT scans, to healthcare providers and patients.

Large multinational companies dominate the market, offering comprehensive imaging solutions, including PET-CT scanners, radiopharmaceuticals, and imaging services. These companies have extensive geographic reach, advanced technology platforms, and strong brand recognition.

Companies may develop and manufacture radiotracers used in PET imaging, either in-house or through partnerships with radiopharmaceutical manufacturers. A diverse portfolio of radiotracers targeting different molecular pathways and clinical indications strengthens a company's position in the market.

• General Electric Company
• Hitachi Ltd.
• Koninklijke Philips N.V.
• Mediso Ltd.
• PerkinElmer, Inc.
• Positron Corporation
• Shimadzu Corporation
• Siemens AG
• Toshiba Corporation
• Yangzhou Kindsway Biotech Co. Ltd

By Type

• Bench-top
• Stationary Scanners
• Portable Scanners/Mobile Scanners

By Application

• Oncology
• Neurology
• Cardiology
• Others

By Region

• North America
• Europe
• Asia Pacific
• The Middle East and Africa